Analytical methods and QbD: A Perfect Match | IVT - - BioPharm International


Analytical methods and QbD: A Perfect Match | IVT

Validation Week

IVT’s 19th Annual
Validation Week

October 22-24, 2013
San Diego, California

Brochure | Register


More in GMPs/Validation

There is general consensus that the execution of an analytical method is, in fact, a process. As with all processes, the quality of the output (in this case a reportable value) depends on various controllable and noise factors. Over the last few years, there has been increasing regulatory emphasis on QbD for manufacturing processes (e.g., FDA¹s 21st century initiatives, FDA¹s draft guidance on process validation guidance, and ICH Q8-9). These initiatives focus on scientific knowledge building, risk assessment, good design, demonstration of performance, and life-cycle manufacturing process management. It is inevitable that these will increasingly become expectations for analytical method processes as well.

While it is important to focus on regulatory expectations, there is another good reason to take a 21st century approach to analytical methods. We, as professionals who support the health care industry have a responsibility to the public to assure the best possible healthcare systems. They should be efficient, safe and effective. In the case of analytical methods that comes down to reliable reportable values with known uncertainty. These reportable values are used to make key decisions that affect the health and safety of the public. To make those decisions optimally requires that the uncertainty in the reported value to be understood. A reportable result whose value is in the middle of the acceptable range is desirable. Even more desirable is that the uncertainty associated with that value be a small fraction of the acceptable range. Otherwise, the reportable value contributes little to the decision and, at worst, may lead to bad decisions.

So the message here is to take pride in good analytical methods.  They are the foundation of knowledge building and the basis on which our pharmaceutical and in vitro diagnostics systems are based. Develop them with powerful scientific tools such as designed experiments. Incorporate prior knowledge for optimal decision making. Validate/Verify/Transfer  them using statistical equivalence tests that provide genuine evidence of quality. Monitor them using control charts to keep them in control. Take the long view of analytical methods and continue to build a strong knowledge base for them; to learn from history and improve their quality at every opportunity.

This article was originally published in IVT - Read original article

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here